NASDAQ:WVE

Wave Life Sciences Stock News

etoro logo Buy WVE
*Your capital is at risk
$5.76
+0.0700 (+1.23%)
At Close: Jun 03, 2026
mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120101
Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.
CAMBRIDGE, Mass., March 19, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q4 2020 Results - Earnings Call Transcript
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -7.27% and -30.61%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Strong execution in 2020 sets stage for advancing five clinical programs and novel ADAR editing modality in 2021
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battli
Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battli
Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q3 2020 Results - Earnings Call Transcript
Results from all cohorts of PRECISION-HD1 and PRECISION-HD2 clinical trials and initial OLE data on track for 1Q 2021
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE